目的 探討散結(jié)靈膠囊聯(lián)合亮丙瑞林治療子宮肌瘤的臨床療效。方法 選擇2018年1月-2020年12月天津市寧河區(qū)醫(yī)院收治的102例子宮肌瘤患者,按照隨機(jī)數(shù)字表法分為對照組和治療組,每組各51例。對照組患者皮下注射注射用醋酸亮丙瑞林微球,月經(jīng)周期第1天給藥,1支/次,每28天1次,共治療3次;在對照組治療的基礎(chǔ)上,治療組餐前2 h口服散結(jié)靈膠囊,3粒/次,3次/d。所有患者治療12周。觀察兩組患者臨床療效,比較治療前后兩組患者月經(jīng)量、子宮體積、瘤體體積、性激素水平,及血清血管內(nèi)皮生長因子(VEGF)和環(huán)氧合酶-2(COX-2)水平。結(jié)果 治療后,治療組的總有效率明顯高于對照組(P<0.05)。治療后,兩組月經(jīng)量、子宮體積及瘤體體積均明顯減小(P<0.05),且治療組明顯比對照組小(P<0.05)。治療后,兩組性激素黃體生成素(LH)、促卵泡激素(FSH)、雌二醇(E₂)和孕酮(P)水平,及血清VEGF和COX-2水平均明顯降低(P<0.05),且治療組明顯比對照組低(P<0.05)。結(jié)論 散結(jié)靈膠囊聯(lián)合亮丙瑞林治療子宮肌瘤的臨床療效較好,能夠明顯縮小子宮體積和肌瘤體積,改善性激素水平,且安全性較好。

Objective To investigate the clinical efficacy of Sanjieling Capsules combined with leuprorelin in treatment of uterine leiomyoma. Methods Patients (102 cases) with uterine leiomyoma in Ninghe District Hospital from January 2018 to December 2020 were divided into control and treatment group by the random number table method, and each group had 51 cases. Patients in the control group were subcutaneous injection administered with Leuprorelin Acetate Microspheres For injection, from the first day of menstrual cycle, one injection at a time, once every 28 d, totally administered for three times. Patients in the treatment group were po administered with Sanjieling Capsules on the basis of the control group 2 h before meals, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluation was evaluated, the volume of menstrual, uterine, tumor, hormone levels, the levels of serum VEGF and COX-2 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the menstrual volume, uterine volume and tumor volume in two groups were significantly decreased (P < 0.05), and these indexes in the treatment group were significantly smaller than those in the control group (P < 0.05). After treatment, the levels of LH, FSH, E₂ and P, and the levels of serum VEGF and COX-2 were significantly decreased in two groups (P < 0.05), and the levels of these factors in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Sanjieling Capsules combined with leuprorelin has good clinical efficacy in treatment of uterine leiomyoma, which can significantly reduce the volume of uterus and leiomyoma, improve the level of sex hormone, and has good safety.

R984

國家自然科學(xué)基金資助項(xiàng)目（81330088）